No increased in utero and peripartum HIV acquisition risk in HIV-exposed preterm infants.

HIV acquisition risk antiretroviral treatment preterm neonates vertical transmission women living with HIV

Journal

Southern African journal of HIV medicine
ISSN: 2078-6751
Titre abrégé: South Afr J HIV Med
Pays: South Africa
ID NLM: 100965417

Informations de publication

Date de publication:
2023
Historique:
received: 04 06 2023
accepted: 13 08 2023
medline: 6 11 2023
pubmed: 6 11 2023
entrez: 6 11 2023
Statut: epublish

Résumé

Limited data exist on the differential risk of HIV acquisition between infants born preterm versus those born at term to women living with HIV (WLHIV). With a reported increase in preterm delivery among pregnant WLHIV, understanding the risk of vertical transmission of HIV in preterm infants can inform strategies to optimise the timing of diagnostic testing, antiretroviral prophylaxis, and infant feeding. To describe the prevalence and timing of HIV acquisition, in utero versus perinatal, among infants with perinatal HIV exposure born prior to 37 weeks completed gestation age compared to those born at term in the Botswana-based Mpepu study and explore predictors of infant HIV acquisition. Using data extracted from the Mpepu study, we describe the prevalence, timing and risk factors for HIV acquisition in infants born preterm versus those born at term. Fisher exact testing was used to test for differences in prevalence and timing of HIV and a multivariable logistic regression model was used to assess risk factors for infant HIV acquisition. 2866 infants born to WLHIV were included in this secondary analysis. 532 (19%) were born preterm. There was no observed difference in the prevalence of HIV acquisition among infants born preterm versus at term overall (0.8% vs 0.6%, There was no observed increase of in utero and peripartum HIV acquisition among infants born preterm following foetal exposure to HIV compared to those born at term.

Sections du résumé

Background UNASSIGNED
Limited data exist on the differential risk of HIV acquisition between infants born preterm versus those born at term to women living with HIV (WLHIV). With a reported increase in preterm delivery among pregnant WLHIV, understanding the risk of vertical transmission of HIV in preterm infants can inform strategies to optimise the timing of diagnostic testing, antiretroviral prophylaxis, and infant feeding.
Objectives UNASSIGNED
To describe the prevalence and timing of HIV acquisition, in utero versus perinatal, among infants with perinatal HIV exposure born prior to 37 weeks completed gestation age compared to those born at term in the Botswana-based Mpepu study and explore predictors of infant HIV acquisition.
Method UNASSIGNED
Using data extracted from the Mpepu study, we describe the prevalence, timing and risk factors for HIV acquisition in infants born preterm versus those born at term. Fisher exact testing was used to test for differences in prevalence and timing of HIV and a multivariable logistic regression model was used to assess risk factors for infant HIV acquisition.
Results UNASSIGNED
2866 infants born to WLHIV were included in this secondary analysis. 532 (19%) were born preterm. There was no observed difference in the prevalence of HIV acquisition among infants born preterm versus at term overall (0.8% vs 0.6%,
Conclusion UNASSIGNED
There was no observed increase of in utero and peripartum HIV acquisition among infants born preterm following foetal exposure to HIV compared to those born at term.

Identifiants

pubmed: 37928500
doi: 10.4102/sajhivmed.v24i1.1509
pii: HIVMED-24-1509
pmc: PMC10623649
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1509

Informations de copyright

© 2023. The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.

Références

JAMA Pediatr. 2017 Oct 2;171(10):e172222
pubmed: 28783807
BMC Pregnancy Childbirth. 2015 Oct 08;15:246
pubmed: 26450602
Lancet. 2010 Jun 5;375(9730):1954
pubmed: 20578280
AIDS. 2019 Aug 1;33(10):1623-1633
pubmed: 30932959
BMC Public Health. 2013 Apr 27;13:398
pubmed: 23621862
Curr Opin HIV AIDS. 2019 Nov;14(6):442-448
pubmed: 31449090
MMWR Morb Mortal Wkly Rep. 2004 Nov 26;53(46):1083-6
pubmed: 15565017
J Infect Dis. 2013 Feb 15;207(4):612-21
pubmed: 23204173
BMC Pediatr. 2016 Jul 21;16:103
pubmed: 27439303
Lancet Glob Health. 2017 May;5(5):e491-e500
pubmed: 28395844
J Pediatric Infect Dis Soc. 2021 Apr 3;10(3):252-258
pubmed: 32539088
Front Public Health. 2020 Jan 17;7:401
pubmed: 32010656
Int J Epidemiol. 2017 Oct 1;46(5):1678-1689
pubmed: 29040569
BMC Pregnancy Childbirth. 2014 Jan 08;14:7
pubmed: 24397463
Open Forum Infect Dis. 2017 Aug 30;4(4):ofx187
pubmed: 29062860
AIDS. 2018 Jan 14;32(2):243-252
pubmed: 29135577
Lancet Infect Dis. 2006 Nov;6(11):726-32
pubmed: 17067921
J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):1-9
pubmed: 29847475
HIV AIDS (Auckl). 2018 Nov 20;10:253-259
pubmed: 30538583
HIV Med. 2014 Apr;15(4):233-8
pubmed: 24025074
Lancet HIV. 2016 May;3(5):e221-30
pubmed: 27126489
Pediatr Infect Dis J. 2017 Sep;36(9):860-862
pubmed: 28410276
J Acquir Immune Defic Syndr. 2014 Dec 1;67 Suppl 4:S188-94
pubmed: 25436817
J Perinatol. 2010 Nov;30(11):717-23
pubmed: 20336078
J Int AIDS Soc. 2018 May;21(5):e25111
pubmed: 29852062
J Infect Dis. 2011 Aug 15;204(4):506-14
pubmed: 21791651
BJOG. 2010 Oct;117(11):1399-410
pubmed: 20716250
Trop Med Int Health. 2017 Jun;22(6):765-775
pubmed: 28407452
PLoS One. 2018 Feb 22;13(2):e0192805
pubmed: 29470508
N Engl J Med. 2016 Nov 3;375(18):1726-1737
pubmed: 27806243
AIDS. 2021 Jun 1;35(7):1139-1141
pubmed: 33946090

Auteurs

Gbolahan Ajibola (G)

Botswana Harvard AIDS Research Institute, Gaborone, Botswana.

Charlotte Mdluli (C)

Botswana Harvard AIDS Research Institute, Gaborone, Botswana.

Kara Bennett (K)

Bennett Statistical Consulting Inc, New York, United States of America.

Maureen Sakoi (M)

Botswana Harvard AIDS Research Institute, Gaborone, Botswana.

Oganne Batlang (O)

Botswana Harvard AIDS Research Institute, Gaborone, Botswana.

Joseph Makhema (J)

Botswana Harvard AIDS Research Institute, Gaborone, Botswana.

Shahin Lockman (S)

Botswana Harvard AIDS Research Institute, Gaborone, Botswana.
Department of Infectious Diseases, Brigham and Womens Hospital, Boston, United States of America.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, United States of America.

Roger Shapiro (R)

Botswana Harvard AIDS Research Institute, Gaborone, Botswana.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, United States of America.

Landon Myer (L)

Department of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

Kathleen Powis (K)

Botswana Harvard AIDS Research Institute, Gaborone, Botswana.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, United States of America.
Department of Internal Medicine and Pediatrics, Massachusetts General Hospital, Boston, United States of America.

Classifications MeSH